Biotechnology Analyst Stringer, along with Dr. Mehta, Chief of Pain Management at NY-Presbyterian/Weill Cornell Medical Center, discuss Vertex’s VX-548 Pain Program on an Analyst/Industry conference call to be held on December 7 at 11 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- MaxCyte price target raised to $10 from $7 at BTIG
- Needham biotechnology analyst to hold an analyst/industry conference call
- Vertex says Health Canada grants expanded use of Kalydeco
- Vertex announces EMA validation for marketing authorization of KAFTRIO
- Vertex Pharmaceuticals announces EC approval of KAFTRIO/ivacaftor combination